The finalised version of a draft circular on changes to blood handling charges circulated to recipients in the Department of Health referred to a likely date of 1 September 1991 to commence HCV screening rather than the 1 July date which had previously been communicated. Read more about The finalised version of a draft circular on changes to blood handling charges circulated to recipients in the Department of Health referred to a likely date of 1 September 1991 to commence HCV screening rather than the 1 July date which had previously been communicated.
Dr Arthur Codd, consultant virologist at the PHLS in Newcastle stated "I understand that you will soon be screening blood donors for hepatitis C in advance of other transfusion centres" and inquired as to his proposed start date. Read more about Dr Arthur Codd, consultant virologist at the PHLS in Newcastle stated "I understand that you will soon be screening blood donors for hepatitis C in advance of other transfusion centres" and inquired as to his proposed start date.
The NBTS National Management Committee meeting noted that the ACTTD had received conflicting advice on the range of available confirmatory tests available. Dr Gunson offered to prepare a policy paper for the Committee after the next meeting of the ACVSB, by which time the evaluation of second-generation tests might have been completed. Read more about The NBTS National Management Committee meeting noted that the ACTTD had received conflicting advice on the range of available confirmatory tests available. Dr Gunson offered to prepare a policy paper for the Committee after the next meeting of the ACVSB, by which time the evaluation of second-generation tests might have been completed.
Professor Cash wrote to Dr Gunson that the recent development (ie the additional pilot stage) leading to a start date in September 1991, "has the SNBTS Directors' fullest support." Read more about Professor Cash wrote to Dr Gunson that the recent development (ie the additional pilot stage) leading to a start date in September 1991, "has the SNBTS Directors' fullest support."
Mr Macleod of the NHS Procurement Directorate wrote to Dr Gunson that the Department of Health had agreed that "there should be a 'second-round' comparative evaluation of Hepatitis C kits at the Newcastle, North London and Glasgow Regional Transfusion Centres with confirmatory testing to be carried out at the University College and Middlesex Hospital School of Medicine", to be completed by the end of April 1991. Read more about Mr Macleod of the NHS Procurement Directorate wrote to Dr Gunson that the Department of Health had agreed that "there should be a 'second-round' comparative evaluation of Hepatitis C kits at the Newcastle, North London and Glasgow Regional Transfusion Centres with confirmatory testing to be carried out at the University College and Middlesex Hospital School of Medicine", to be completed by the end of April 1991.
A letter from Dr Contreras to Dr Gunson expressed reluctance to start screening due to financial issues. Read more about A letter from Dr Contreras to Dr Gunson expressed reluctance to start screening due to financial issues.
Dr Lloyd wrote to colleagues saying that Dr Gunson was looking for all red blood cells available for issue to be Hepatitis C negative by 30 June 1991, which would mean starting testing some weeks in advance. Read more about Dr Lloyd wrote to colleagues saying that Dr Gunson was looking for all red blood cells available for issue to be Hepatitis C negative by 30 June 1991, which would mean starting testing some weeks in advance.
Dr Wagstaff wrote to Dr Gunson discussing the earliest date anti-HCV screening could commence. Read more about Dr Wagstaff wrote to Dr Gunson discussing the earliest date anti-HCV screening could commence.
Dr Follett in Glasgow produced a full report of the Ortho and Abbott test kit trial. Read more about Dr Follett in Glasgow produced a full report of the Ortho and Abbott test kit trial.
Peter Savage wrote to inform Dr Gunson that Ortho was shortly to commence clinical trials of a second-generation ELISA test, with improved sensitivity and specificity, and a second-generation RIBA test incorporating additional antigen bands. Read more about Peter Savage wrote to inform Dr Gunson that Ortho was shortly to commence clinical trials of a second-generation ELISA test, with improved sensitivity and specificity, and a second-generation RIBA test incorporating additional antigen bands.